Andera Bullish About Prospects For Europe's Biotechs

Unveils €456m Fund

The France-based firm has assembled a strong syndicate for its sixth generation of 'BioDiscovery' funds, consolidating its position as one of the leading players in life sciences venture capital in Europe.

Andera partners
Olivier Litzka and Sofia Ioannidou • Source: Andera

Europe's biotechs have always held their own when it comes to scientific innovation but despite the tricky climate for financing, there are plenty of firms that have the potential to go from discovery to late-stage development and even commercialization.

That is the view of Sofia Ioannidou and Olivier Litzka, two of the five partners (along with Gilles Nobécourt, Jan...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.